Use of Biologic Therapies in the Treatment of Asthma – A Comparative Real World Data Analysis on Healthcare Resource Utilization and Costs Before and After Therapy Initiation

References

• Steppuhn H, Kuhnert R, Scheidt-Nave C. 12-month prevalence of asthma among adults in Germany. J Health Monit. 2017;2(3):34–42.
   PubMedGoogle Scholar
• Stock S, Redaelli M, Luengen M, Wendland G, Civello D, Lauterbach KW. Asthma: prevalence and cost of illness. Eur Respir J. 2005;25(1):47–53. doi:10.1183/09031936.04.00116203
   PubMed Web of Science ®Google Scholar
• Khan A, Sternbach N, Kamat S, Annunziata K, Jaffe D, Gouia I. Prevalence of asthma in France, Germany, Italy, Spain, and the United Kingdom, based on the 2018 European National Health and Wellness Survey. Chest. 2020;158(4):A27. doi:10.1016/j.chest.2020.08.067
   Web of Science ®Google Scholar
• Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy. 2012;67(7):835–846. doi:10.1111/j.1398-9995.2012.02832.x
   PubMed Web of Science ®Google Scholar
• De Groot JC, Storm H, Amelink M, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016;2(2):1–8. doi:10.1183/23120541.00100-2015
   Google Scholar
• Kuruvilla ME, Lee FEH, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–233. doi:10.1007/s12016-018-8712-1
   PubMed Web of Science ®Google Scholar
• Verhamme KM, Engelkes M, de Ridder M, et al. Characteristics of adult onset vs. late onset asthma - a multinational database cohort study. Eur Respir J. 2017;50:OA316. European Respiratory Society (ERS)
   Google Scholar
• Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49(5):1700634. doi:10.1183/13993003.00634-2017
   PubMed Web of Science ®Google Scholar
• Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006;100(7):1139–1151. doi:10.1016/j.rmed.2006.03.031
   PubMed Web of Science ®Google Scholar
• Numata T, Miyagawa H, Nishioka S, et al. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study. BMC Pulm Med. 2020;20(1):1–10. doi:10.1186/s12890-020-01248-x
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Global Initiative for Asthma; 2019:1–32.
   Google Scholar
• Hamelmann E. Managing severe asthma: a role for the long-acting muscarinic antagonist tiotropium. Biomed Res Int. 2018;2018:7–9. doi:10.1155/2018/7473690
   Web of Science ®Google Scholar
• Global Initiative for Asthma. Difficult-To-Treat and Severe Asthma. 2018.
   Google Scholar
• Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075–2088. doi:10.1080/03007995.2018.1505352
   PubMed Web of Science ®Google Scholar
• Caminati M, Senna G. Uncontrolled severe asthma: starting from the unmet needs. Curr Med Res Opin. 2019;35(2):175–177. doi:10.1080/03007995.2018.1528218
   PubMed Web of Science ®Google Scholar
• Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. doi:10.1183/13993003.00703-2018
   PubMed Web of Science ®Google Scholar
• Cataldo D, Louis R, Michils A, et al. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma. 2021;58(4):448–458. doi:10.1080/02770903.2019.1705335
   PubMed Web of Science ®Google Scholar
• Dalal AA, Duh MS, Gozalo L, et al. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm. 2016;22(7):833–847. doi:10.18553/jmcp.2016.22.7.833
   PubMedGoogle Scholar
• Bloechliger M, Reinau D, Spoendlin J, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19(75). doi:10.1186/s12931-018-0742-y
   PubMed Web of Science ®Google Scholar
• Manka A, Wechsler E. Selecting the right biologic for your patients with severe asthma. Ann Allergy Asthma Immunol. 2018;121(4):406–413. doi:10.1016/j.anai.2018.07.033
   PubMed Web of Science ®Google Scholar
• Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med. 2011;6(1):27–40.
   Google Scholar
• Hashimoto S, Bel EH. Targeting IL-5 in severe asthma: a DREAM come true? Lancet. 2012;380:9842. doi:10.1016/S0140-6736(12)61132-5
   Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. New add-on treatment for patients with severe asthma; 2019. Available from: https://www.ema.europa.eu/en/news/new-add-treatment-patients-severe-asthma. Accessed December 13, 2021.
   Google Scholar
• Mcgregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199(4):433–445. doi:10.1164/rccm.201810-1944CI
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi:10.1111/all.14221
   PubMed Web of Science ®Google Scholar
• Yancey SW, Keene ON, Albers FC, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140(6):1509–1518. doi:10.1016/j.jaci.2017.10.005
   PubMed Web of Science ®Google Scholar
• Federal Statistical Office. Consumer price index for Germany; 2021. Available from: https://www.destatis.de/DE/Themen/Wirtschaft/Konjunkturindikatoren/Basisdaten/vpi002a.html;jsessionid=40B929A485D0E5D39868A57953A14C13.live741?view=main%5BPrint%5D. Accessed May 11, 2021.
   Google Scholar
• Federal Statistical Office. Statistical yearbook 2019, National accounts; 2019. Available from: https://www.destatis.de/DE/Themen/Querschnitt/Jahrbuch/jb-vgr.pdf?__blob=publicationFile. Accessed May 11, 2021.
   Google Scholar
• Federal Statistical Office. National accounts, major macroeconomic variables in billions of Euros, rate of change in gross domestic product (GDP); 2021. Available from: https://www.destatis.de/DE/Themen/Wirtschaft/Volkswirtschaftliche-Gesamtrechnungen-Inlandsprodukt/Tabellen/inlandsprodukt-gesamtwirtschaft.html. Accessed May 11, 2021.
   Google Scholar
• Caminati M, Vaia R, Furci F, Guarnieri G, Senna G. Uncontrolled asthma: unmet needs in the management of patients. J Asthma Allergy. 2021;14:457–466. doi:10.2147/JAA.S260604
   PubMed Web of Science ®Google Scholar
• Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma Worldwide: data from the International severe asthma registry. Chest. 2020;157(4):790–804. doi:10.1016/j.chest.2019.10.053
   PubMed Web of Science ®Google Scholar
• Breekveldt-Postma NS, Erkens JA, Aalbers R, Van De Ven MJT, Lammers JWJ, Herings RMC. Extent of uncontrolled disease and associated medical costs in severe asthma - A PHARMO study. Curr Med Res Opin. 2008;24(4):975–983. doi:10.1185/030079908X280518
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890. doi:10.1016/S2213-2600(14)70201-2
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled Phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556. doi:10.1016/S2213-2600(16)30031-5
   PubMed Web of Science ®Google Scholar
• Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56(4):2000151. doi:10.1183/13993003.00151-2020
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, Chanez P, et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019;122(1):41–49.e2. doi:10.1016/j.anai.2018.08.005
   PubMed Web of Science ®Google Scholar
• Hossny E, Caraballo L, Casale T, El-Gamal Y, Rosenwasser L. Severe asthma and quality of life. World Allergy Organ J. 2017;10(1):28. doi:10.1186/s40413-017-0159-y
   PubMed Web of Science ®Google Scholar
• Niven RM, Saralaya D, Chaudhuri R, et al. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open. 2016;6(8):e011857. doi:10.1136/bmjopen-2016-011857
   PubMed Web of Science ®Google Scholar
• Britton M, Howes T, Saralaya D, et al. Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: real-life data from 3 UK centres. Eur Respir J. 2012;40(Suppl 56).P227.
   PubMedGoogle Scholar
• Langner I, Ohlmeier C, Zeeb H, Haug U, Riedel O. Individual mortality information in the German Pharmacoepidemiological Research Database (GePaRD): a validation study using a record linkage with a large cancer registry. BMJ Open. 2019;9(7):1–7. doi:10.1136/bmjopen-2018-028223
   PubMed Web of Science ®Google Scholar
• Hartmann J, Weidmann C, Biehle R. Validierung von GKV-Routinedaten am Beispiel von geschlechtsspezifischen Diagnosen [Validation of SHI Claims Data Exemplified by Gender-specific Diagnoses]. Das Gesundheitswesen. 2016;78(10):e162–e167. German.
   Google Scholar
• Globale Initiative für Asthma. Global Strategy for Asthma Management and Prevention; 2016.
   Google Scholar